Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases
Brun, B.; Kuentz, M.; Man, N.G.; Feuilhade, F.; Bierling, P.; Vernant, J.P.; Farcet, J.P.; Cordonnier, C.; Reyes, F.; Dreyfus, B.; Rochant, H.
Presse Medicale 12(19): 1205-1210
1983
ISSN/ISBN: 0755-4982 PMID: 6221296 Document Number: 215839
The results of a combination chemotherapy trial (melphalan, CCNU, vincristine, cyclophosphamide) involving 28 patients with stage III (n = 21) or stage II (n = 7) multiple myeloma suggest a high response rate, with a mean 71% malignant cell destruction in 78.5% of the patients. A longer survival in responsive stage III patients as compared with patients treated with alkylating agents seems likely, but this can only be established by a randomized trial. Despite haematological side-effects, this combination therapy may be used in high risk patients, especially those resistant to a single alkylating agent and in whom the frequency, intensity and duration of responses appears to be the same as in previously untreated patients. In contrast, only one of the 7 patients treated for relapse after previous response to a single alkylating agent responded to the combination chemotherapy.